Lindagan, Sayba M.
HRN: 07-62-08 Sex: FemalePatient Encounter
AMS Audit List
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/22/2025
CEFTRIAXONE 1G (VIAL)
10/22/2025
10/29/2025
IV
2g
OD
UTI
Waiting Final Action
10/28/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
10/28/2025
11/03/2025
IV
2.25gm
Q8
Septicemia Sec To CUTI
Checking Final Appropriateness
10/28/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
10/28/2025
11/05/2025
IV
2.25g
Q8h
Complicated UTI
Checking Final Appropriateness
10/28/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
10/28/2025
10/28/2025
IV
350mg
Now
Complicated Uti
Checking Final Appropriateness